NASDAQ
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $3.71B and net income of $313.75M for FY 2025. The gross profit margin is 81.8% with a net profit margin of 8.4%.
Financial data for ALNY
65.19% YoY
212.79% YoY
209.63% YoY
Annual Income Statement for ALNY
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $4B | $2B | $2B | $1B | $844M |
| Cost of Revenue | $677M | $323M | $310M | $169M | $140M |
| Gross Profit | $3B | $2B | $2B | $869M | $704M |
| Operating Expenses | $3B | $2B | $2B | $2B | $1B |
| Operating Income | $502M | -$177M | -$282M | -$785M | -$709M |
| Net Income | $314M | -$278M | -$440M | -$1B | -$853M |
| EPS | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| EBITDA | $631M | -$179M | -$258M | -$927M | -$662M |
No price data available for this timeframe.